Avita Medical (RCEL) Upgraded to Buy: Here's What You Should Know
AI Sentiment
Highly Positive
9/10
as of 02-24-2026 4:00pm EST
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.
| Founded: | N/A | Country: | United States |
| Employees: | 226 | City: | VALENCIA |
| Market Cap: | 132.0M | IPO Year: | N/A |
| Target Price: | $7.17 | AVG Volume (30 days): | 196.9K |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $3.22 - $10.28 | Next Earning Date: | 01-01-0001 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 21.69% | Revenue Growth (next year): | 49.58% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
RCEL Breaking Stock News: Dive into RCEL Ticker-Specific Updates for Smart Investing
AI Sentiment
Highly Positive
9/10
See how RCEL stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "RCEL Avita Medical Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.